CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
about
Prostanoid receptor antagonists: development strategies and therapeutic applicationsAnalgesic and anti-inflammatory properties of novel, selective, and potent EP4 receptor antagonists.Prostaglandin E(2) binding peptide screened by phage displaying: a new therapeutic strategy in rheumatoid arthritisPharmacokinetic/pharmacodynamic evaluation of grapiprant in a carrageenan-induced inflammatory pain model in the rabbit.The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache.Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functionsNew drugs for migraineA Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with OsteoarthritisRisk management profile of etoricoxib: an example of personalized medicineBGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.Prostaglandin EP4 antagonists.Targeting cell surface trafficking of pain-facilitating receptors to treat chronic pain conditions.AKAP-dependent sensitization of Ca(v) 3.2 channels via the EP(4) receptor/cAMP pathway mediates PGE(2) -induced mechanical hyperalgesiaA novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models.Simultaneous Inhibition of PGE2 and PGI2 Signals Is Necessary to Suppress Hyperalgesia in Rat Inflammatory Pain Models.Mapping PTGERs to the Ovulatory Follicle: Regional Responses to the Ovulatory PGE2 Signal.Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammationFunctional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine.Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice.Pharmacokinetics of grapiprant, a selective EP4 prostaglandin PGE2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats.Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs.Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis.Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs.Prostaglandin E2 induces immediate migraine-like attack in migraine patients without aura
P2860
Q33485483-1AFBDB38-930D-4C54-B78C-BB94718E8D42Q33777968-3424E418-B4DD-465B-9778-34DFB4F300F6Q33899147-8729C539-3288-43CB-8F6D-BBD8E66B919DQ34546785-8241C275-9C34-49CD-90E2-523B87BBFE3EQ35214562-C11035BB-58BE-4DD1-8124-30B1A03A7FCDQ35713568-82716260-924B-40BD-9691-2A82299DFE8DQ36332611-4F8D2EAD-DE5E-4B7F-9AF0-C698F4DF3745Q37020247-ACA915FC-4367-4990-9912-E7B271CA619AQ37052864-37CC2929-464D-4E6C-A262-70BBBC3A3793Q37230998-288F3258-9AA7-4D44-BDB0-594FFEA83267Q38162977-847F032F-9198-4A76-A538-B875C226668DQ38186775-76DD80AF-3D6E-4F3F-A13B-80DADD3F3700Q39290501-E78BDA5F-AF4C-4B9F-AD3B-2BCE4935AC8BQ39710252-BC256C6D-D8AB-4FCE-8FD3-659CCBD61F59Q40094568-369AC301-FE5B-422E-BC83-5D54C66C136EQ41132032-14CC7D9C-2472-4B6A-82C9-26CC4AE0CDA3Q42682734-1500B315-975E-4861-93D9-EB3652165BB0Q42936119-202A3D53-3675-460B-AFF8-0B1AC693F06EQ46306888-D025197C-35C3-404C-A3C1-86F23ADE4CEFQ46374097-A53846C6-1453-4384-91AC-698EFC49400BQ46493256-7CA8DA59-6F82-49DC-81D1-0FEEAF02202BQ46579864-8184D721-B707-4DF5-BCC5-410B4344D015Q47990585-4F7FDF32-FE38-4D80-B230-B8C7A1DEF8F2Q57023979-A70861A5-D183-4631-9022-63A0D4835088
P2860
CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CJ-023,423, a novel, potent an ...... h antihyperalgesic properties.
@en
type
label
CJ-023,423, a novel, potent an ...... h antihyperalgesic properties.
@en
prefLabel
CJ-023,423, a novel, potent an ...... h antihyperalgesic properties.
@en
P2093
P356
P1476
CJ-023,423, a novel, potent an ...... h antihyperalgesic properties.
@en
P2093
Akio Murase
Hiroyuki Ohshiro
Junji Takada
Kana Taniguchi
Kazunari Nakao
Masatoshi Masuda
Takako Okumura
Tomoki Kato
Yoko Murata
Yoshiyuki Okumura
P304
P356
10.1124/JPET.107.122010
P407
P577
2007-05-10T00:00:00Z